Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTADEG1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS 3	JUN 06	KOREAPAT updated with 41,000 documents
NEWS 4	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS 5	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS 6	JUN 25	CA/CAplus and USPAT databases updated with IPC reclassification data
NEWS 7	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS 8	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS 9	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS 10	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS 11	JUL 28	CA/CAplus patent coverage enhanced
NEWS 12	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS 13	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 14	JUL 28	STN Viewer performance improved
NEWS 15	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS 16	AUG 13	CA/CAplus enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS 17	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS 18	AUG 15	CAplus currency for Korean patents enhanced
NEWS 19	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information
NEWS 20	SEP 18	Support for STN Express, Versions 6.01 and earlier, to be discontinued
NEWS 21	SEP 25	CA/CAplus current-awareness alert options enhanced to accommodate supplemental CAS indexing of exemplified prophetic substances
NEWS 22	SEP 26	WPIDS, WPINDEX, and WPIX coverage of Chinese and and Korean patents enhanced
NEWS 23	SEP 29	IFICLS enhanced with new super search field
NEWS 24	SEP 29	EMBASE and EMBAL enhanced with new search and display fields
NEWS 25	SEP 30	CAS patent coverage enhanced to include exemplified prophetic substances identified in new Japanese-language patents
NEWS 26	OCT 07	EPFULL enhanced with full implementation of EPC2000
NEWS 27	OCT 07	Multiple databases enhanced for more flexible patent number searching

```
 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:41:17 ON 07 OCT 2008

=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 14:41:37 ON 07 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    6 OCT 2008  HIGHEST RN 1057750-28-3
DICTIONARY FILE UPDATES:   6 OCT 2008  HIGHEST RN 1057750-28-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10-565048genA.str
```





chain nodes :
9 10 11 12 13 14 17
ring nodes :
1 2 3 4 5 6 7 8
chain bonds :
7-10 8-9 8-17 10-11 11-12 11-13 11-14
ring bonds :
1-2 1-7 2-3 2-8 3-4 4-5 5-6 5-8 6-7
exact/norm bonds :
1-2 1-7 2-3 2-8 3-4 4-5 5-6 5-8 6-7 11-12 11-13 11-14
exact bonds :
7-10 8-9 8-17 10-11

G1:Cb,Hy,Ak

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 17:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS

L1 STR



G1 Cb,Hy,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss full
FULL SEARCH INITIATED 14:42:37 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 172 TO ITERATE

100.0% PROCESSED 172 ITERATIONS 70 ANSWERS
SEARCH TIME: 00.00.01

L2 70 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 178.82 179.03

FILE 'CAPLUS' ENTERED AT 14:42:45 ON 07 OCT 2008

FILE COVERS 1907 - 7 Oct 2008 VOL 149 ISS 15
FILE LAST UPDATED: 6 Oct 2008 (20081006/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l2
L3 7 L2

```
=> s l3 and acetylcholine
         79069 ACETYLCHOLINE
            74 ACETYLCHOLINES
         79090 ACETYLCHOLINE
                  (ACETYLCHOLINE OR ACETYLCHOLINES)
L4            3 L3 AND ACETYLCHOLINE

=> d l4 1-3 abs ibib hitstr

L4   ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2008 ACS on STN
GI
```



I

AB Title compds. [I; R1, R2 = (substituted) Ph, thienyl, pyridyl, PhCH2, pyrimidinyl, thiazolyl, isothiazolyl, cycloalkyl, etc.; R3 = H, OH; X = physiol. acceptable anion], were prepared for treatment of chronic obstructive pulmonary disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, emphysema, and allergic rhinitis (no data). Thus, 2-[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-1,1-bis(3-methyl-2-thienyl)ethanol (preparation given) was treated with MeBr in tert-Bu Me ether to give 61% (3-endo)-3-[2-hydroxy-2,2-bis(3-methyl-2-thienyl)ethyl]-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide.

ACCESSION NUMBER: 2007:146107 CAPLUS
DOCUMENT NUMBER: 146:229203
TITLE: Preparation of azoniabicyclooctanes as M3 muscarinic acetylcholine receptor antagonists.
INVENTOR(S): Busch-Petersen, Jakob; Laine, Dramane Ibrahim; Palovich, Michael R.; Davis, Roderick S.; Fu, Wei; Xie, Haibo
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 42pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007016639	A2	20070208	WO 2006-US30153	20060802
WO 2007016639	A3	20070705		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,

CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

EP 1937267 A2 20080702 EP 2006-800674 20060802

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR

PRIORITY APPLN. INFO.: US 2005-704579P P 20050802
WO 2006-US30153 W 20060802

OTHER SOURCE(S): MARPAT 146:229203

IT 924646-68-4P 924646-70-8P 924646-72-0P
924646-74-2P 924646-76-4P 924646-78-6P
924655-67-4P 924655-70-9P 924655-72-1P
924655-73-2P 924655-75-4P 924655-77-6P
924655-78-7P 924655-80-1P 924655-81-2P
924655-82-3P 924655-83-4P 924655-84-5P
924655-85-6P 924655-89-0P 924655-90-3P
924655-91-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of azoniabicyclooctanes as M3 muscarinic acetylcholine receptor antagonists)

RN 924646-68-4 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 3-[2-hydroxy-2,2-bis(3-methyl-2-thienyl)ethyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 924646-70-8 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 3-[2-hydroxy-2,2-bis(3-methoxyphenyl)ethyl]-8,8-dimethyl-, iodide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● I^-

RN 924646-72-0 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[2-hydroxy-2,2-bis(4-methyl-3-thienyl)ethyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 924646-74-2 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[2-hydroxy-2,2-bis(5-methyl-2-thienyl)ethyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 924646-76-4 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[2,2-bis(5-chloro-2-thienyl)-2-hydroxyethyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 924646-78-6 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[2,2-bis[5-(difluoromethyl)-2-thienyl]-2-hydroxyethyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 924655-67-4 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[2,2-bis(3-fluorophenyl)-2-hydroxyethyl]-8,8-dimethyl-, iodide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● I^-

RN 924655-70-9 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[2,2-bis(5-fluoro-2-methylphenyl)-2-hydroxyethyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 924655-72-1 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-(2-hydroxy-2,2-di-3-thienylethyl)-8,8-dimethyl-, iodide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● I^-

RN 924655-73-2 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[2,2-bis(3,4-difluorophenyl)-2-hydroxyethyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 924655-75-4 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[2,2-bis(3,5-difluorophenyl)-2-hydroxyethyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 924655-77-6 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[2,2-bis(5-fluoro-2-methoxyphenyl)-2-hydroxyethyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 924655-78-7 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[2,2-bis(3-fluoro-2-methylphenyl)-2-hydroxyethyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 924655-80-1 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-(2,2-dicyclohexyl-2-hydroxyethyl)-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 924655-81-2 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-(2,2-dicyclopentyl-2-hydroxyethyl)-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 924655-82-3 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[3-(2-fluorophenyl)-2-[(2-fluorophenyl)methyl]-2-hydroxypropyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 924655-83-4 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-(2-hydroxy-2,2-di-2-pyridinylethyl)-8,8-dimethyl-, iodide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● I^-

RN 924655-84-5 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[2,2-bis(4-fluorophenyl)-2-hydroxyethyl]-8,8-dimethyl-, iodide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● I^-

RN 924655-85-6 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[2,2-bis(4-chlorophenyl)-2-hydroxyethyl]-8,8-dimethyl-, iodide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● I^-

RN 924655-89-0 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[2,2-bis(3-chlorophenyl)-2-hydroxyethyl]-8,8-dimethyl-, iodide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● I^-

RN 924655-90-3 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[2,2-bis(2,3-difluorophenyl)-2-hydroxyethyl]-8,8-dimethyl-, iodide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● I^-

RN 924655-91-4 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[2-(2,3-dichlorophenyl)-2-hydroxy-2-phenylethyl]-8,8-dimethyl-, iodide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● I^-

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
GI



I

AB Title compds. [I; R1, R2 = (substituted) Ph, thienyl, pyridyl, PhCH2, pyrimidinyl, thiazolyl, isothiazolyl, cycloalkyl, etc.; X = pharmaceutically acceptable counterion], were prepared for treatment of

COPD, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, emphysema, and allergic rhinitis (no data). Thus, (endo)-3-[2,2-bis(3-hydroxyphenyl)ethenyl]-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide was prepared from tri-Me phosphonoacetate, tropinone, MeI, and 3-methoxyphenylmagnesium bromide.

ACCESSION NUMBER: 2007:144089 CAPLUS
DOCUMENT NUMBER: 146:229182
TITLE: Preparation of 3-(arylethenyl)-8,8-dimethyl-8-azoniabicyclo[3.3.1]octanes as M3 muscarinic acetylcholine receptor antagonists.
INVENTOR(S): Busch-Petersen, Jakob; Laine, Dramane Ibrahim; Palovich, Michael R.; Davis, Roderick S.; Fu, Wei; Xie, Haibo
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 35pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007016650	A2	20070208	WO 2006-US30218	20060802
WO 2007016650	A3	20070531		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
EP 1937230	A2	20080702	EP 2006-789274	20060802
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR				
US 20080234315	A1	20080925	US 2008-997451	20080131
PRIORITY APPLN. INFO.:			US 2005-704578P	P 20050802
			WO 2006-US30218	W 20060802

OTHER SOURCE(S): MARPAT 146:229182
IT 924646-91-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of arylethenyldimethylazoniabicyclooctanes as M3 muscarinic acetylcholine receptor antagonists)
RN 924646-91-3 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[2-hydroxy-2,2-bis(2-methoxyphenyl)ethyl]-8,8-dimethyl-, iodide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● I^-

IT 924646-68-4P 924646-70-8P 924646-72-0P
924646-74-2P 924646-76-4P 924646-78-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of arylethenyldimethylazoniabicyclooctanes as M3 muscarinic acetylcholine receptor antagonists)
RN 924646-68-4 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[2-hydroxy-2,2-bis(3-methyl-2-thienyl)ethyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 924646-70-8 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[2-hydroxy-2,2-bis(3-methoxyphenyl)ethyl]-8,8-dimethyl-, iodide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● I^-

RN 924646-72-0 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[2-hydroxy-2,2-bis(4-methyl-3-thienyl)ethyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 924646-74-2 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[2-hydroxy-2,2-bis(5-methyl-2-thienyl)ethyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 924646-76-4 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[2,2-bis(5-chloro-2-thienyl)-2-hydroxyethyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 924646-78-6 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[2,2-bis[5-(difluoromethyl)-2-thienyl]-2-hydroxyethyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

AB Muscarinic acetylcholine receptor antagonists, e.g., (3-endo)-3-(2-hydroxy-2,2-diphenylethyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide and methods of using them are provided. In addition a pharmaceutical composition for the treatment of muscarinic acetylcholinereceptor-mediated diseases comprising the above compound is disclosed.

ACCESSION NUMBER: 2005:99316 CAPLUS
DOCUMENT NUMBER: 142:183475
TITLE: Muscarinic acetylcholine receptor antagonists
INVENTOR(S): Belmonte, Kristen E.; Busch-Petersen, Jakob; Laine, Dramane; Palovich, Michael R.
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005009362	A2	20050203	WO 2004-US23041	20040716
WO 2005009362	A3	20050407		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004259238	A1	20050203	AU 2004-259238	20040716
CA 2532433	A1	20050203	CA 2004-2532433	20040716
EP 1648461	A2	20060426	EP 2004-778509	20040716
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1822839	A	20060823	CN 2004-80020652	20040716
BR 2004012537	A	20060919	BR 2004-12537	20040716

JP 2007525478	T	20070906	JP 2006-520387		20040716
IN 2006DN00077	A	20070824	IN 2006-DN77		20060104
MX 2006PA00663	A	20060330	MX 2006-PA663		20060117
US 20060178396	A1	20060810	US 2006-565048		20060117
NO 2006000777	A	20060411	NO 2006-777		20060217
PRIORITY APPLN. INFO.:			US 2003-487982P	P	20030717
			WO 2004-US23041	W	20040716

OTHER SOURCE(S): MARPAT 142:183475

IT 90114-71-9 102133-77-7 106655-98-5
106713-93-3 106954-22-7 834882-84-7
834882-85-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(muscarinic acetylcholine receptor antagonists)

RN 90114-71-9 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 3-(2-hydroxy-2,2-di-2-thienylethyl)-8,8-dimethyl-, bromide, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 102133-77-7 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 3-[2-hydroxy-2-phenyl-2-(2-thienyl)ethyl]-8,8-dimethyl-, bromide, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 106655-98-5 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 3-(2-hydroxy-2,2-diphenylethyl)-8,8-dimethyl-, bromide, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 106713-93-3 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-(2-cyclohexyl-2-hydroxy-2-phenylethyl)-8,8-dimethyl-, bromide, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 106954-22-7 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[2-hydroxy-2-phenyl-2-(2-pyridinyl)ethyl]-8,8-dimethyl-, bromide, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 834882-84-7 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-(3-cyclohexyl-2-hydroxy-2-phenylpropyl)-

8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



RN 834882-85-8 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-(2-hydroxy-2,2-diphenylethyl)-8,8-dimethyl-, (3-endo)-, salt with 4-methylbenzenesulfonic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 805224-99-1
CMF C23 H30 N O

Relative stereochemistry.



CM 2

CRN 16722-51-3
CMF C7 H7 O3 S



=> log off
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
STN INTERNATIONAL LOGOFF AT 14:44:43 ON 07 OCT 2008